Burlingame, Calif.-based Color Genomics most recently raised $80 million, its intended funding total. This funding brings the company’s total financing to $150 million, making it one of the most well-funded health technology companies in Silicon Valley, according to CNBC.
The funding comes from investors like General Catalyst, CRV’s George Zachary and Laurene Powell Jobs, founder and president of Emerson Collective.
Color Genomics’ tests evaluate users for risk of cancer and heart disease, similar to other genomics companies. However, it plans to distinguish itself by exploring preventive tests for neurological health, behavioral health, and family and reproductive medicine.
More articles on data analytics & precision medicine:
NIH certifies Vibrent Health’s precision medicine platform
Cancer Treatment Centers of America expands efforts with Foundation Medicine in precision medicine project
Researchers examine how precision medicine may prevent suicide
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
